Recent news on Interferon Alfacon-1

Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study  -  Dec 12, 2006
Genetic Engineering News (press release),Alpha interferons, including Interferon alfacon-1, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Use of daily interferon alfacon-1 (integren, CIFN) plus ribavirin in patients infected with hepatitis C who are nonresponders to previous pegylated

Valeant Pharmaceuticals Presents End-of-Treatment Results of ...  Oct 30, 2006
Alpha interferons, including Interferon alfacon-1, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders ... -PharmaLive.com (press release), Zacks.com announces that Richard Rhodes highlights the following ...  Sep 12, 2006
They manufacture and market four human therapeutic products, EPOGEN(R) (Epoetin alfa), NEUPOGEN(R) (Filgrastim), INFERGEN(R) (Interferon alfacon-1) and STEMGEN ... -Business Wire

Valeant Pharmaceuticals Initiates Infergen® Phase 4 Study  -  12 Dec 2006
Business Wire (press release),Alpha interferons, including Interferon alfacon-1, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious

Clinical Advances in Hepatitis B and Hepatitis C  -  Dec 6, 2006
Medscape (subscription)Use of daily interferon alfacon-1 (integren, CIFN) plus ribavirin in patients infected with hepatitis C who are nonresponders to previous pegylated



FDA Sends Intermune Letter Over Advertisement  Apr 4, 2006
...retinal hemorrhages and cotton wool spots; optic neuritis, and papilledema are induced or aggravated by treatment with Interferon alfacon-1 or other alpha ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional